Another one! Peptide products drive 'hot' performance, Sanuo Biological's net profit for the first three quarters is expected to increase by 76%.

①Peptide active pharmaceutical ingredients and formulation products are selling well, driving Shen Nuo Biotech's net income in the first three quarters to reach as high as 61.1987 million yuan, with the highest year-on-year increase of 75.88%. ②In September of this year, Shen Nuo Biotech signed a GLP-1 peptide active pharmaceutical ingredient supply contract worth up to 0.35 billion yuan, with a performance period until December 31, 2025.

cls.cnOct 9 10:22 ET

Livzon Pharmaceutical Group Inc. expects reduced performance pressure in the second half of the year | Live coverage of the earnings conference

① At the results meeting, Yang Liang, director of Lizhu Group, responded to issues such as the year-on-year decline in the company's revenue and financial data in various segments; ② Tang Yanggang, president of the company, said that the overall market size of tocilizumab injections in China is small.

cls.cnSep 10 07:50 ET

Another unreasonable suppression! The U.S. House of Representatives has passed the Biosecurity Act, and wuxi apptec and wuxi bio have quickly responded.

①The U.S. House of Representatives passed the draft of the Biosecurity Act (H.R.8333) with 306 votes in favor and 81 votes against. ②Wuxi Apptec, Wuxi Bio, and other companies strongly opposed it. ③This bill still needs to be voted on by the Senate and the versions passed by both houses need to be reconciled before it can be submitted to the U.S. President for signing into law.

cls.cnSep 9 21:06 ET

The decline in the pharmaceutical sector is affecting overall revenue. Fosun Pharma: Will focus on building super 1 billion yuan big varieties | Earnings conference highlights.

Fosun Pharma's revenue from innovative drugs in the first half of the year exceeded 3.7 billion yuan, accounting for about 18% of the overall revenue. Wu Yifang revealed that the business of innovative drugs will strive to achieve a compound annual growth rate of 30% in the next few years. Wu Yifang said that the privatization of Henlius is currently underway, and the entire business and pipeline of Henlius will be deeply integrated with Fosun Pharma through privatization.

cls.cnAug 28 19:29 ET

Hybio Pharmaceutical's H1 revenue continues to decline. Are active pharmaceutical ingredients becoming a 'lifesaver' for large orders? | Interpretations

①In the first half of this year, the revenue decline trend of Hybio Pharmaceutical has not been stopped, and the net profit loss has narrowed to some extent; ②The revenue of the formulation sector continues to decline due to the impact of block orders for main products, and the revenue contribution of the active pharmaceutical ingredient sector has become the first; ③In the first half of this year, Hybio Pharmaceutical has made some efforts to alleviate the cash flow.

cls.cnAug 23 08:58 ET

Why is Fosun Pharma privatizing Henlius at this time? | Jianzhi Research

The suspension of Henlius stocks has finally been resolved, consistent with previous market rumors: Fosun Pharma will privatize Henlius for delisting, with a privatization valuation of approximately RMB 12.4 billion. Fosun Pharma's bid for each share of Henlius is HKD 24.60, a premium of 30.6% over its pre-suspension closing price. Based on last year's net profit of CNY 546 million for Henlius, this privatization has a PE ratio of approximately 23 times. The total transaction is HKD 5.4 billion, which will use no more than HKD 3.7 billion in acquisition loans. Henlius has a total share capital of 543.5 million shares, including 163.4 million H shares and 380.1 million non-listed shares. The tenderer in this case is Fosun.

wallstreetcnJun 25 03:26 ET